|
May 13
|
BridgeBio Pharma Presents Additional Data and Analyses from its Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at ESC-HF, Including That Acoramidis Treatment Significantly Reduced All-Cause Mortality in a Pre-specified Sen...
|
|
May 4
|
What You Need To Know About The BridgeBio Pharma, Inc. (NASDAQ:BBIO) Analyst Downgrade Today
|
|
May 3
|
BridgeBio Pharma First Quarter 2024 Earnings: Beats Expectations
|
|
May 3
|
BridgeBio Oncology Therapeutics launches with $200m funding
|
|
May 2
|
BridgeBio Pharma Reports First Quarter 2024 Financial Results and Business Update
|
|
May 2
|
BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with $200M of private external capital to accelerate the development of its novel precision oncology pipeline
|
|
May 2
|
BridgeBio spinout launches with $200M for KRAS cancer drugs
|
|
May 1
|
Pfizer’s strong Vyndaqel sales draw attention to rare disease drug’s patent life
|
|
Apr 25
|
Will BridgeBio Pharma (BBIO) Report Negative Q1 Earnings? What You Should Know
|
|
Apr 7
|
BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
|
|
Mar 27
|
TipRanks’ ‘Perfect 10’ List: These 3 Top-Scoring Stocks Are Sending a Bullish Signal
|
|
Mar 6
|
BridgeBio Pharma Announces Pricing of Public Offering of Common Stock
|
|
Mar 5
|
Bayer (BAYRY) Acquires BridgeBio's Cardiovascular Drug
|
|
Mar 4
|
BridgeBio Pharma Announces Proposed Public Offering of Common Stock
|
|
Mar 4
|
BridgeBio Dives After Inking A $310 Million Deal With Bayer For Its Lead Drug
|
|
Mar 4
|
Bayer pays $310M to buy into BridgeBio heart drug
|
|
Mar 4
|
BridgeBio Pharma, Bayer agree on licensing deal for heart disease drug in Europe
|
|
Mar 4
|
BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM
|
|
Feb 2
|
BridgeBio Pharma Shares Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Including No Mortality Reported in the Trial at 30 Months
|
|
Jan 30
|
Invitae Partners with BridgeBio Pharma to Harness Genetic Insights for the Discovery of Rare Disease Therapeutics
|